Fritextsökning
Artiklar per år
Innehållstyper
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
KVA:s nya preses – ”Forskning är en livsstil”
Under sommaren tillträdde Birgitta Henriques Normark som preses för Kungliga Vetenskapsakademien. Life Science Sweden träffade henne i Vetenskapsakademiens pampiga byggnad vid Frescati i Stockholm i slutet av maj för att prata om forskning och om hennes nya uppdrag.
-
Biosimilarer ger prispress, men används de tillräckligt?
Biosimilarernas ankomst för drygt 16 år sedan väckte hopp om att många fler patienter skulle få tillgång till effektiva men annars mycket dyra behandlingar med biologiska läkemedel. Så hur bra har svensk sjukvård varit på att använda biosimilarerna? Svaret beror, åtminstone delvis, på vem man frågar.
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.
-
Pharmnovo startar kliniska studier – och förstärker sitt team
I augusti startade läkemedelsbolaget Pharmnovo kliniska studier av bolagets läkemedelskandidat mot nervsmärta. Nu meddelar bolaget att de stärker upp organisationen med Tommy Nilsson som CFO och Jarkko Kalliomäki som ledare för det kliniska arbetet.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Studie med läkemedel mot nervsmärta startar
Lundaföretaget Pharmnovo påbörjar nu kliniska studier med sin läkemedelskandidat mot neuropatisk smärta.
-
Sweden is heavily criticised for not ordering Covid vaccine
Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.
-
Redaktionens sommartips – böcker, poddar och tv-serier
Nu stundar sommar, semester och äntligen en chans att läsa den där boken, lyssna på den där podden eller se den där filmen som inte hanns med tidigare. Här tipsar Life Science Swedens redaktion om lämpligt tidsfördriv eller förkovran under årets mest avkopplande dagar.
-
Collaboration for a simpler production of gene therapies launched
A collaboration between universities and companies aims at providing better production methods for the development of gene therapies. The initiative is led by Johan Rockberg, Professor at KTH.
-
Ny metod för mikroskopi öppnar genväg till nya läkemedel
Forskare vid Chalmers har utvecklat en helt ny mikroskopiteknik för att kunna studera de minsta biologiska partiklarna i sitt naturliga tillstånd – och därmed öppna vägar för snabbare utveckling av nya läkemedel och vaccin.
-
Ny CBO hos Bioinvent
Cancerforskningsföretaget Bioinvent har rekryterat Sylvie Ryckebusch till rollen som Chief Business Officer.
-
Nyemission ska ta Pharmnovos behandling mot nervsmärta till klinisk prövning
Lundbaserade Pharmnovo har tagit in 67 miljoner kronor i en nyemission för att finansiera vidare utveckling av bolagets läkemedelskandidat mot nervsmärta.
-
The first vaccine derived from cowpox
The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the world’s first smallpox vaccination, and a medical breakthrough had occurred.
-
Noxious parasite forms hybrids and deceives the immune system
The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to deceive the immune system by forming new variants that are mixtures of different strains.
-
Eva Arlander rekryteras av Index Pharmaceuticals
Läkemedelsutvecklaren Index Pharmaceuticals har anställt Eva Arlander som Chief Development Officer och medlem i bolagets nya ledningsgrupp. Samtidigt genomförs flera andra personalförändringar.
-
Paolo Macchiarini in court – “The sole intent was to cure”
Paolo Macchiarini’s surgical procedure was illegal, life-threatening and caused severe and prolonged suffering to patients the prosecution claimed when the trial against the Italian surgeon began on Wednesday last week.
-
When carelessness, forgetfulness and coincidence become the researcher’s best friend
Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advances have come about thanks to completely random incidents and the open-mindedness of scientists
-
Studie: Immunsystemet känsligt i månader efter mild covid-19
En mild infektion av covid-19 kan leda till långvariga besvär. Enligt en ny studie kan makrofager få ett förändrat inflammatoriskt och metaboliskt uttryck under flera månader efter infektion av sars-cov-2.
-
Elicera develops CAR-T against solid tumours – may become the first in the world
Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method. “Almost half of them have
-
Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages
For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridiculed by the medical establishment. However, from our perspective today, we can sum it up with the saying: He who laughs last laughs best, writes Samuel Lagercrantz in an editorial.
-
Ny vd till Wntresearch
Pernilla Sandwall har utsetts till Wntresearchs nya vd. Hon efterträder Anders Rabbe och tillträder i april.
-
Study: An objective diagnosis of constant tinnitus may be possible
A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tinnitus, which was demonstrated in a study made by researchers at the Karolinska Institute.